clinical applications of tms copy not
TRANSCRIPT
![Page 1: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/1.jpg)
Clinical Applications of TMS
&Evidence in Depression
2553480Adam Stern, M.D. Director of Psychiatric Applications
Berenson-Allen Center for Noninvasive Brain Stimulation, BIDMC
Instructor in PsychiatryHarvard Medical School
PLEASE D
O NOT C
OPY
![Page 2: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/2.jpg)
Overview
• TMS Basics in Psychiatry
• TMS studies in depression
• Treatment program at BIDMC
PLEASE D
O NOT C
OPY
![Page 3: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/3.jpg)
Disclosures
Research has been supported by
Harvard Catalyst / The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR001102) and financial contributions from Harvard University and its affiliated academic health centers. The content is solely the responsibility of the author and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the National Institutes of Health.
NARSAD Young Investigator Grant from the Brain and Behavior Research Foundation
PLEASE D
O NOT C
OPY
![Page 4: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/4.jpg)
Disclosures (cont.)
• TMS has been approved for treatment in treatment-resistant depression though we may discuss other uses which have not been FDA approved.
• Some portion of the material has been shared by other members of the BA-CNBS and are used with permission.
• I have no financial conflicts to report.
PLEASE D
O NOT C
OPY
![Page 5: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/5.jpg)
What is the need for non-invasive brain stimulation?
PLEASE D
O NOT C
OPY
![Page 6: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/6.jpg)
6
1st century
1900
’50s ’60s ’70s ’80s ’90s’30s ’40s
“Black Bile” ECT TCAs MAOIs SSRIs
LithiumHeterocyclics
PharmacologicRefinements
Developments in Medical Treatment of Depression
Courtesy of: ASCP Psychopharmacology Curriculum: “Electroconvulsive Therapy”
PLEASE D
O NOT C
OPY
![Page 7: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/7.jpg)
What about Electroconvulsive therapy (ECT)?
Image courtesy of: http://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies.shtml
• Many decades of safety and efficacy data
• Gold Standard for treatment-resistant depression
• Invasive stimulation requiring anesthesia with frequent cognitive adverse effects
• Enormous stigma
PLEASE D
O NOT C
OPY
![Page 8: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/8.jpg)
A.T. Barker1984 PLE
ASE DO N
OT COPY
![Page 9: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/9.jpg)
Electro-Magnetic Induction
“I think I got hold of a good thing”
M. Faraday29 August 1831
PLEASE D
O NOT C
OPY
![Page 10: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/10.jpg)
Stimulation Coils
PLEASE D
O NOT C
OPY
![Page 11: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/11.jpg)
EquipmentRepetitive Stimulators
PLEASE D
O NOT C
OPY
![Page 12: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/12.jpg)
Topographic resolution
PLEASE D
O NOT C
OPY
![Page 13: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/13.jpg)
Stern AP, Cohen D. Neuropsychiatry 2013. PLEASE D
O NOT C
OPY
![Page 14: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/14.jpg)
Scalp to Brain Relation
PLEASE D
O NOT C
OPY
![Page 15: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/15.jpg)
TMS Parameters
PLEASE D
O NOT C
OPY
![Page 16: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/16.jpg)
rTMS:Lasting Modulation of Cortical Activity
ShamTMS
TMS
1 HzTMS
20 HzTMS
Valero et al. 2002PLEASE D
O NOT C
OPY
![Page 17: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/17.jpg)
Therapeutic Applications of rTMS
• Depression• Bipolar Disorder• OCD• PTSD• Schizophrenia• Auditory Hallucinoses• Pain
– Visceral pain– Atypical facial pain– Phantom pain
• PD• Focal dystonia• Epilepsy
– Myoclonic epilepsy– Focal status
epilepticus
• Stuttering• Tics• Neurorehabilitation
– Neglect– Aphasia– Hand weaknessPLE
ASE DO N
OT COPY
![Page 18: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/18.jpg)
Potential Adverse Effects• Common:
– Headache– Auditory effects
• Rare– Seizure induction– Effects on Cognition– Mania– Endocrine effects
Safety GuidelinesMonitoring
PLEASE D
O NOT C
OPY
![Page 19: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/19.jpg)
2013_______BrainswayDeepTMS
FDA cleared
PLEASE D
O NOT C
OPY
![Page 20: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/20.jpg)
rTMS in Depression
• Kolbinger et al. 1993, 95
• Grisaru et al. 1994
• George et al. 1996
• Pascual-Leone et al. 1996– Double Blind
– Multiple Control Conditions
– 17 patients
– 9/17 with ∂HDRS > 50%
Lancet 1996PLEASE D
O NOT C
OPY
![Page 21: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/21.jpg)
rTMS for depression treatmentEfficacy - Review
Gershon, Dannon and Grunhaus (Am J Psychiatry 2003; 160:835–845)
PLEASE D
O NOT C
OPY
![Page 22: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/22.jpg)
PLEASE D
O NOT C
OPY
![Page 23: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/23.jpg)
Sen-Star Treatment Link4 key functions:
* Contact sensing to ensure treatment coil is positioned correctly
* Magnetic field confirmation to ensure patient receives desired treatment
* Surface field cancellation to reduce stimulation of the scalp
* Charge approximately $100 per treatment
PLEASE D
O NOT C
OPY
![Page 24: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/24.jpg)
Stimulation Parameters
10 pulses/sec120% of motor threshold3000 pulses/session4–6 weeksIron-core coil
PLEASE D
O NOT C
OPY
![Page 25: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/25.jpg)
PLEASE D
O NOT C
OPY
![Page 26: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/26.jpg)
PLEASE D
O NOT C
OPY
![Page 27: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/27.jpg)
Phase IDrug-FreeLead-In7-10 days
Phase IIAcute Treatment Phase
6 weeks
Phase IIITaper Phase
3 weeks
Primary Timepoint @ 4 weeks
Durability of Effect @ 9 weeks
[TMS Taper + Open-label AD Mono-Rx]
Study 101 Trial DesignRandomized, Double-blind, Sham-Controlled
Secondary Timepoint @ 6 weeks
NeuroStar TMS Therapy(N=155)
Sham TMS (N=146)
Randomization
n=325
PLEASE D
O NOT C
OPY
![Page 28: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/28.jpg)
PLEASE D
O NOT C
OPY
![Page 29: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/29.jpg)
PLEASE D
O NOT C
OPY
![Page 30: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/30.jpg)
PLEASE D
O NOT C
OPY
![Page 31: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/31.jpg)
PLEASE D
O NOT C
OPY
![Page 32: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/32.jpg)
How does TMS compare to other approaches for treatment-resistant depression?
• Olanzapine/Fluoxetine (Thase, 2007): 0.33
• Aripiprazole (Marcus, 2008): 0.34
• Neurostar TMS Therapy (Demitrack, 2009): 0.52
• Brainsway DeepTMS (Levkovitz, 2015): 0.76
• Electroconvulsive Therapy (UK ECT Review Group, 2003): 0.91
PLEASE D
O NOT C
OPY
![Page 33: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/33.jpg)
Brainsway DeepTMS: A New Device
PLEASE D
O NOT C
OPY
![Page 34: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/34.jpg)
CONSORT
PLEASE D
O NOT C
OPY
![Page 35: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/35.jpg)
Levkovitz, et al. World Psychiatry 2015;14:64–73
DeepTMS HDRS Change
PLEASE D
O NOT C
OPY
![Page 36: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/36.jpg)
PLEASE D
O NOT C
OPY
![Page 37: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/37.jpg)
Is this as good as it gets? Probably Not.
Oliveira-Maia A, Press DZ, Pascual-Leone A. (preliminary/submitted): Modulation of motor cortex excitability predicts antidepressant response to prefrontal cortex repetitive transcranial magnetic stimulation.
PLEASE D
O NOT C
OPY
![Page 38: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/38.jpg)
What about Stim. Target?
PLEASE D
O NOT C
OPY
![Page 39: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/39.jpg)
Patient Referral
• For patients with medication resistant depression
• Must be under care of psychiatrist
• Referral form on tmslab.org or call: 667-0307
PLEASE D
O NOT C
OPY
![Page 40: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/40.jpg)
Initial Evaluation
• Referral from treating psychiatrist• Neurology
– Contraindications– Effect of medication on TMS
• Psychiatry– Caution if: Psychotic depression, bipolar, personality
disorders– At least one adequate trial of antidepressant medication
PLEASE D
O NOT C
OPY
![Page 41: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/41.jpg)
PLEASE D
O NOT C
OPY
![Page 42: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/42.jpg)
Consent
• Discussion of on-label vs. off-label treatment
• Explanation of side-effects– Seizure– Headache– Neck pain– Scalp pain
PLEASE D
O NOT C
OPY
![Page 43: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/43.jpg)
Initiation Phase
• Treatments daily (excluding weekends)• Various mood assessments
daily/weekly/monthly • Minimum 2 weeks• Maximum 4-6 weeks
PLEASE D
O NOT C
OPY
![Page 44: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/44.jpg)
Assessment tools
• Beck, Hamilton, Analogue scale• Target symptoms• Clinician evaluation of patient• Other sources of information (e.g. family, referring
psychiatrist)• Side effects questionnaire
• Weekly meeting of all staff to discuss progress
PLEASE D
O NOT C
OPY
![Page 45: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/45.jpg)
Alternatives being investigated
• Choosing protocol on clinical parameters (anxiety, risk of mania/sz)
• Using rs-fMRI guidance for targeting• Using anatomical MRI to help with intensity of
stimulation (particularly in elderly)• Plasticity measures as guide• Others: mood induction, more than one
session/day
PLEASE D
O NOT C
OPY
![Page 46: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/46.jpg)
PLEASE D
O NOT C
OPY
![Page 47: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/47.jpg)
Maintenance Phase
• Minimal evidence (absence of evidence, not evidence of absence)
• Relapse prevention– Start with weekly treatment– Gradually space out sessions
• “Watchful Waiting”– Patient presents when feeling worse
PLEASE D
O NOT C
OPY
![Page 48: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/48.jpg)
Cost
• Insurance coverage depends on location– Medicare jurisdiction– Private payers
• Additional fee for assessments• Helping with billing, talking with payers
PLEASE D
O NOT C
OPY
![Page 49: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/49.jpg)
PLEASE D
O NOT C
OPY
![Page 50: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/50.jpg)
Conclusions
• TMS can be used to affect brain circuitry• TMS has potential therapeutic effects for
certain neuropsychiatric disorders • It is FDA cleared for treatment of medication
resistant depression• Our clinical program is on forefront of
treatment (bidmc.org/tms or tmslab.org)
PLEASE D
O NOT C
OPY
![Page 51: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/51.jpg)
I am confident that I know how to refer patients for rTMS
• Mean 2.71 (3.5 is neutral)• Disagree 69.9%, Agree 30.1%
PLEASE D
O NOT C
OPY
![Page 52: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/52.jpg)
•Mean 3.76•Disagree 31.6%, Agree 68.4% (even though they don’t know how!)
I will likely refer patients for TMS in the future
PLEASE D
O NOT C
OPY
![Page 53: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/53.jpg)
• Mean 2.30• Residents 2.05, Faculty 2.52 (p<0.01)• Academic 2.20, Community 2.59 (p=0.092)
approaches significance
I am confident that TMS is covered by most insurance plans
PLEASE D
O NOT C
OPY
![Page 54: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/54.jpg)
I feel that TMS is an effective treatment for treatment-resistant depression:
• Mean 3.82
PLEASE D
O NOT C
OPY
![Page 55: Clinical Applications of TMS COPY NOT](https://reader031.vdocument.in/reader031/viewer/2022020913/62035d53e8a11f7ee03ee3bc/html5/thumbnails/55.jpg)
•Mean 2.89
I know and understand the FDA indications for TMS use in treatment-resistant depression:
PLEASE D
O NOT C
OPY